View : 93 Download: 0
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041)
- Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041)
- Lee, Jung-Yun; Park, Jeong-Yeol; Park, Sang Yoon; Lee, Jeong-Won; Kim, Jae Weon; Kim, Yong Beom; Jeong, Dae Hoon; Lee, Kwang-Beom; Kim, Tae-Hun; Lee, In Ho; Choi, Min Chul; Kim, Ki Hyung; Kim, Yong-Man; Lee, Yong Jae; Kang, Sokbom; Pujade-Lauraine, Eric; Shin, So-Jin; Hong, Dae Gy; Shim, Seung-Hyuk; Kim, Yun Hwan; Song, Taejong; Bae, Jaeman; Lee, Jong-Min; Lee, San Hui; Lee, Eun-Ju; Park, Sang-Il; Lee, Sung-Jong; Lee, Chulmin; Lee, Taek Sang; Chang, Suk-Joon; Kim, Min Kyu; KGOG Investigators
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- GYNECOLOGIC ONCOLOGY
- GYNECOLOGIC ONCOLOGY vol. 152, no. 1, pp. 61 - 67
- Ovarian cancer; Platinum-resistant; Bevacizumab; Chemotherapy; Real world
- ACADEMIC PRESS INC ELSEVIER SCIENCE
- SCI; SCIE; SCOPUS
- Document Type
- Purpose. To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum resistant ovarian cancer in a real-world setting. Patients and methods. We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan) between 2015 and 2017 for second- or third-line chemotherapy in routine clinical practice. The primary endpoint was progression-free survival (PFS) and safety. Secondary endpoints included the objective response rate (ORR), PFS2, overall survival, duration of chemotherapy, and reasons for discontinuing chemotherapy. Results. Of 391 patients, 259 (66.2%) received bevacizumab with PLD, 94 (24.0%) with topotecan, and 38 (9.7%) with weekly paclitaxel. The median PFS was 6.1 months with all forms of bevacizumab-containing therapy. Although the cohort with weekly paclitaxel had a better PFS than the PLD cohort (P = 0.028), this finding was not found in patients with a previous platinum-free interval of less than three months. The median duration of therapy was five cycles (range, one to 20 cycles), and 29 patients (7.4%) discontinued treatment because of adverse events from bevacizumab-containing regimens. The PLD cohort had fewer grade >= 3 adverse events than the other regimens (PLD, 35.8%; weekly paclitaxel, 52.6%; topotecan, 51.1%; P = 0.012), especially events of hematologic toxicities. Conclusion. In Korean ovarian cancer patients, the safety and effectiveness of chemotherapy with bevacizumab in a real-world setting was consistent with the results from a randomized controlled study. The effectiveness and toxicity profiles varied among the chemotherapy regimens, and this finding should be considered in practice. (C) 2018 Elsevier Inc. All rights reserved.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.